fbpx
previous arrow
next arrow
Slider

Premaitha Health PLC
(“Premaitha,” the “Company” or the “Group”)

Full year results to 31 March 2018 and half-year trading update

Manchester, UK – 28 September 2018: Premaitha (AIM: NIPT), a leading international molecular diagnostics group, announces its full year results for the twelve months ended 31 March 2018; and provides an update on trading in the current financial year to date.  

Financial highlights

Revenues increased by 100% to £6.15m (2017: £3.08m), including the first full year of contribution from Yourgene Bioscience (“Yourgene”), which was acquired in March 2017

○ Revenues increased by 35% on a like-for-like basis

● Gross profit increased by 250% to £3.17m (2017: £1.28m)
● Gross margin improved 10 points to 52% (2017: 42%) due to benefits of scale, geographic mix and reduced product costs
● General administrative expenses increased 27% to £8.96m (2017: £7.08m), due to the full year inclusion of Yourgene

○ Total administrative expenses £11.80m (2017: £8.89m) after litigation expenses, share-based payments and acquisition costs

● Operating loss before litigation expenses reduced by 18% to £5.91m (2017 loss: £7.22m)

○ Operating loss after litigation expenses increased to £8.60m (2017: £7.60m)
○ Litigation settled post year end as announced on 19 September 2018

● Cash of £0.28m at 31 March 2018 (31 March 2017: £1.30m)

○ Additional £3.0m equity raised in May 2018
○ £2.0m loan funding secured from Thermo Fisher in February 2018
○ Further £2.5m raise announced today

Operational highlights

● IONA® test volumes increased by 108% to 50,000 (2017: 24,000)
● Successfully expanded footprint, with strong contract momentum, including in new territories in Asia, the Middle East and Africa
● Launch of Sage™ by Yourgene, a cost-effective, flexible non-invasive prenatal testing (“NIPT”) solution incorporating additional prenatal screening analysis tools
● Post period-end:

○ Signed agreement with clinical laboratory group in India to provide a  bespoke, high quality and scalable NIPT solution to the Indian market
○ Appointed Mr Lyn Rees as Chief Executive Officer of the Group
○ Premaitha announced a legal settlement and licence agreement (the “Agreements”) with Illumina, resolving the current NIPT patent infringement litigation
○ Appointment of Hayden Jeffreys to a senior commercial role within the Group

Trading update

Six month revenues to 30 September 2018 expected to be up approximately 40% to £3.8m (H1 2017: £2.6m)
● Test volumes for the first half are expected to be in excess of 34,000 (H1 2017: 22,000), demonstrating significant momentum
● Continue to expand geographic footprint, securing agreements in Kenya and India in the first six months
● Settlement agreements signed with Illumina removes the litigation overhang from the business and opens up a significantly larger addressable market for a multi-partner business model

Adam Reynolds, Non-executive Chairman of Premaitha Health, commented:

“I am delighted with the strategic and commercial progress that we have achieved in the period, having doubled revenues, increased gross profit by 250%, and continued our significant geographic expansion.

“Previously, the litigation has detracted from this progress, but the partnership agreement secured post period-end with Illumina, means that we are now free to operate globally in the NIPT market, and can fully focus on growing the business. We now have the optimal team in place and are extremely well-positioned to execute on our growth strategy in order to capitalise on the opportunity that exists for Premaitha both in the rapidly expanding market for NIPT, and beyond.”

A copy of the 2018 Annual Report and Accounts has been uploaded to the Company's website at https://www.premaitha.com/.

For shareholders who have opted to received printed copies of the Annual report and Accounts, these are being posted today.  

This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014.

For more information, please contact:    

Premaitha Health PLC
Lyn Rees, Chief Executive Officer
Barry Hextall, Chief Financial Officer
Joanne Cross, Head of Marketing
This email address is being protected from spambots. You need JavaScript enabled to view it. 
Tel: +44 (0)161 667 1053

Cairn Financial Advisers LLP (NOMAD)
Liam Murray / James Caithie
Tel: +44 (0)20 7213 0880

finnCap (Broker)
Geoff Nash / Matthew Radley (Corporate Finance)
Tim Redfern (Corporate Broking)
Tel: +44 (0)20 7220 0500

Vigo Communications
Ben Simons / Fiona Henson / Antonia Pollock
This email address is being protected from spambots. You need JavaScript enabled to view it.
Tel: +44 (0)20 7390 0234

About Premaitha

Premaitha is an international molecular diagnostics group which uses the latest advances in DNA analysis technology to develop safer, faster and regulatory approved genetic screening tests.
 
The Group's current primary focus is on non-invasive prenatal tests (NIPT) for pregnant women - an emerging, multi-billion dollar global market - although the Group intends to expand its product range into other areas of clinical genetics.
 
Premaitha's first product, the IONA® test was launched in 2015 as the first CE-IVD NIPT test in Europe. It enables laboratories and healthcare practitioners to offer a complete CE-marked NIPT system in-house. The IONA® test is performed on a maternal blood sample - which contains traces of fetal DNA - and estimates the risk of a fetus being affected with Down's syndrome or other genetic conditions.
 
Unlike existing prenatal screening methods, due to its high level of accuracy, the IONA® test can significantly reduce the number of women subjected to unnecessary invasive follow up diagnostic procedures, such as amniocentesis, which are costly, resource intensive and carry a risk of miscarriage.
 
In March 2017, Premaitha acquired Yourgene Bioscience, a specialist next generation sequencing and bioinformatics company based in Taiwan, with its own NIPT screening solution that operates on the same Thermo Fisher next-generation sequencing platform as Premaitha's IONA® test. Yourgene brings significant benefits to the Group through expanded market access in Asia - the world's fastest growing NIPT market - as well as opportunities for cross-selling and the ability to jointly develop expanded test content both within NIPT and beyond.
 
From May 2018, the Group will trade as Yourgene Health outside of Europe (but remaining as Yourgene Bioscience in Taiwan) reflecting the increased scope of the business in other areas of clinical genetics further to reproductive health; but will maintain the Premaitha Health brand within Europe.
 
Premaitha is headquartered in Manchester, England, with Yourgene offices in Taipei and Singapore. Its shares trade on the AIM market of the London Stock Exchange (AIM: NIPT). For further information, please visit www.premaitha.com. Follow us on twitter @PremaithaHealth.

  • 30 June 2020 - COVID-19 assay launched +

    Yourgene Health plc

    (“Yourgene” or the “Group” or the “Company”)

    COVID-19 assay launched
    Launch of Clarigene™ SARS-CoV-2 test (‘RUO’)

    Manchester, UK – 30 June 2020: Yourgene (AIM: YGEN), a leading international molecular diagnostics group, announces the launch of its Clarigene™ SARS-CoV-2 test for research use only (‘RUO’).

    The Clarigene™ SARS-CoV-2 test is a molecular PCR (polymerase chain reaction) based COVID-19 assay, which detects the SARS-CoV-2 virus RNA* to confirm the presence of the virus. The test

    Read More
  • 16 June 2020 - Collaboration in COVID-19 testing +

    Yourgene Health plc

    (“Yourgene” or the “Group” or the “Company”)

    Collaboration in COVID-19 testing
    Supporting the effort to get Britain back to work

    Manchester, UK – 16 June 2020: Yourgene (AIM: YGEN), a leading international molecular diagnostics group, announces a collaboration agreement with international payments company Caxton and immunity passport app Prova, which once launched will support the efforts to get Britain back to work by testing employees for COVID-19.

    The collaboration with Prova and Yourgene

    Read More
  • 15 June 2020 - CE-IVD mark received for Illumina-based IONA® test +

    Yourgene Health plc

    (“Yourgene” or the “Group” or the “Company”)

    CE-IVD mark received for Illumina-based IONA ® test
    Non-invasive prenatal screening test to launch as IONA ® Nx

    Manchester, UK – 15 June 2020: Yourgene (AIM: YGEN), a leading international molecular diagnostics group, announces that it has received CE-IVD marking for its Illumina-based IONA ® test, the Company’s flagship non-invasive prenatal test (“NIPT”) product for Down’s syndrome and other genetic disorders.

    The newly approved test, the IONA ® Nx NIPT

    Read More
  • 26 May 2020 - Yourgene COVID-19 testing service launch and business update +

    Yourgene Health plc

    (“Yourgene” or the “Group” or the “Company”)

    Yourgene COVID-19 testing service launch and business update

    Manchester, UK – 26 May 2020: Yourgene (AIM: YGEN), a leading international molecular diagnostics group, announces it has expanded its laboratory capabilities to offer COVID-19 testing service and it is developing its own COVID-19 test kit and targeting a pipeline of opportunities. In addition, the Company provides an update on its wider business activities.

    Yourgene testing laboratories have

    Read More
  • 20 April 2020 - Year-end Trading update: Revenues increase 86% +

    Yourgene Health plc

    (“Yourgene” or the “Group” or the “Company”)

    Year-end Trading update: Revenues increase 86%

    Manchester, UK – 20 April 2020: Yourgene (AIM: YGEN), a leading international molecular diagnostics group, announces a trading update for the year ended 31 March 2020.

    Revenues for the year ended 31 March 2020 were £16.6m (2019: £8.9m), up 86% compared to the previous year, and does not include £0.4m of orders for March that fell into the new financial

    Read More
  • 7 April 2020 - Presentation on ‘Adapting during crisis’ +

    Yourgene Health plc

    (“Yourgene” or the “Group” or the “Company”)

    Presentation on ‘Adapting during crisis’

    Manchester, UK – 7 April 2020: Yourgene Health (AIM: YGEN), a leading international molecular diagnostics group, announces that Hayden Jeffreys, Chief Operating Officer of Yourgene Health, will be presenting at 4pm today at the virtual webinar event ‘Adapting during crisis’ hosted by Bruntwood Sci-Tech.

    Bruntwood Sci-Tech will be joined by its customers from across Manchester and Innovation Birmingham who have adapted

    Read More
  • 25 March 2020 - Contract manufacturing agreement for COVID-19 diagnostic test +

    Yourgene Health plc

    (“Yourgene” or the “Group” or the “Company”)

    Contract manufacturing agreement for COVID-19 diagnostic test

    Manchester, UK – 25 March 2020: Yourgene (AIM: YGEN), a leading international molecular diagnostics group, announces the signing of an agreement for contract manufacturing services with Novacyt S.A. (“Novacyt”, EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, to support the production of COVID-19 diagnostic tests developed by Primerdesign, Novacyt’s molecular diagnostics division.

    Yourgene will make use

    Read More
  • 10 March 2020 - Acquisition of French distribution channel & Direct Subscription to raise £2.5m +

    THIS ANNOUNCEMENT, INCLUDING THE APPENDICES, AND THE INFORMATION CONTAINED WITHIN THEM, IS RESTRICTED AND IS NOT FOR PUBLIC RELEASE, PUBLICATION, OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA, JAPAN, THE REPUBLIC OF SOUTH AFRICA OR ANY OTHER STATE OR JURISDICTION IN WHICH SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL. PLEASE SEE THE IMPORTANT NOTICES AT THE END OF THIS ANNOUNCEMENT.
     
    THIS ANNOUNCEMENT CONTAINS
    Read More
  • 17 February 2020 - CE Marking Technical File submission +

    Yourgene Health plc
    (“Yourgene” or the “Company”)

    CE Marking Technical File submission

    Manchester, UK – 17 February 2020: Yourgene (AIM: YGEN), a leading international molecular diagnostics group, announces that it has submitted its CE Marking Technical File for the Illumina-based IONA ® test to its EU notified body, BSI Netherlands.

    BSI Netherlands will now audit the CE Marking Technical File and if accepted will issue a European CE Marking Certificate. As soon as regulatory approvals are received
    Read More
  • 14 February 2020 - Medilink Award win for Outstanding Achievement  +

    Yourgene Health plc

    (“Yourgene” or the “Group” or the “Company”)

    Medilink Award win for Outstanding Achievement

    Manchester, UK – 14 February 2020: Yourgene (AIM: YGEN), a leading international molecular diagnostics group, announces it has won the Outstanding Achievement Award at the Medilink North of England Healthcare Business Awards 2020, held at the Lowry Hotel in Manchester , yesterday.

    The Outstanding Achievement Award is presented to a Company for an achievement that has had a significant or vital

    Read More
  • 14 February 2020 - TGA approves DPYD for sale in Australia +

    Yourgene Health plc

    (“Yourgene” or the “Group” or the “Company”)

    TGA approves DPYD for sale in Australia

    Southern Cross, Yourgene’s Australian distributor , to sell the chemotoxicity diagnostic assay in the Territory

    Manchester, UK – 14 February 2020: Yourgene (AIM: YGEN), a leading international molecular diagnostics group, announces that its chemotoxicity diagnostics assay – Elucigene DPYD - which tests to identify cancer patients at risk of lethal side effects from chemotherapy, has been approved for sale in Australia (‘the

    Read More
  • 5 December 2019 - The Healthcare+ Expo Taiwan +

    Yourgene Health plc

    (“Yourgene” or the “Group” or the “Company”)

    The Healthcare+ Expo Taiwan

    Manchester, UK – 5 December 2019: Yourgene (AIM: YGEN), a leading international molecular diagnostics group, announces it will be exhibiting and presenting at The Healthcare+ Expo Taiwan, from the 5-8 December 2019 at stand R241, Hall 2 in the Taipei Nangang Exhibition Centre, Taiwan City, Taiwan.

    The Expo brings together over 600 exhibitors, working in the advanced medicine and leading technology space

    Read More
  • 2 December 2019 - Half-year Report +

    This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014. 

    Yourgene Health plc 

    (“Yourgene”, the “Company” or the “Group”) 

    Half-year Report 

    Manchester, UK – 2 December 2019: Yourgene Health plc (AIM: YGEN), the international molecular diagnostics group which commercialises genetic products and services, announces its unaudited half year report for the six months ended 30 September 2019, in line with expectations. 

    The results reflect strong organic growth as well as a

    Read More
  • 29 November 2019 - Bionow Double Award Wins +

    Yourgene Health plc

    (“Yourgene” or the “Group” or the “Company”)

    Bionow Double Award Wins

    Manchester, UK – 29 November 2019 : Yourgene (AIM: YGEN), a leading international molecular diagnostics group, announces it has won Bionow Investment Deal of Year and Bionow Company of the Year at the 18th Annual Bionow Awards ceremony, held at The Mere Golf Resort & Spa in Cheshire yesterday.

    The Bionow Investment Deal of Year, sponsored by QIAGEN, is an award presented to

    Read More
  • 28 November 2019 - Opening of New Facilities and Corporate HQ  +

    Yourgene Health plc

    (“Yourgene” or the “Group” or the “Company”)

    Opening of New Facilities and Corporate HQ  

    Manchester, UK – 28 November 2019:  Yourgene (AIM: YGEN), a leading international molecular diagnostics group, announces the official opening of its newly integrated facilities and corporate HQ at Citylabs 1.0, in the centre of Manchester’s genomics campus, and continued expansion with a planned further increase in headcount at the Company’s UK headquarters.

    The establishment of the new Company

    Read More
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
Pregnant lady sitting at table with Laptop

Media & Investor Relations
Walbrook PR Ltd
4 Lombard Street
London
EC3V 9HD
yourgene@walbrookpr.com
T : +44 (0)20 7933 8780

Two business people looking at computer screen